GSE168043
Host-dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
RNA-Seq comparison of Dacomitinib resistant PC9 lung adenocarcinoma cells vs the parental cells. Overall design: PC9 cells were treated with increasing concentration of dacomitinib (from 1 pM to 100 nM) for 6 months. Dacomitinib resistant cells treated with Dacomitib (100 nM) were compared to the Parental PC9 cells.